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PHACE syndrome is the association of large segmental facial hemangiomas and congenital anomalies, such as
posterior fossa malformations, cerebral arterial anomalies, coarctation of the aorta, eye anomalies, and sternal
defects. To date, the reported cases of PHACE syndrome have been sporadic, suggesting that PHACE may have a
complex pathogenesis. We report here genomic copy number variation (CNV) analysis of 98 individuals with
PHACE syndrome as a first step in deciphering a potential genetic basis of PHACE syndrome. A total of 3,772
CNVs (2,507 duplications and 1,265 deletions) were detected in 98 individuals with PHACE syndrome. CNVs were
then eliminated if they failed to meet established criteria for quality, spanned centromeres, or did not contain
genes. CNVs were defined as ‘‘rare’’ if not documented in the database of genomic variants. Ten rare CNVs were
discovered (size range: 134–406 kb), located at 1q32.1, 1q43, 3q26.32-3q26.33, 3p11.1, 7q33, 10q24.32, 12q24.13,
17q11.2, 18p11.31, and Xq28. There were no rare CNV events that occurred in more than one subject. Therefore,
further study is needed to determine the significance of these CNVs in the pathogenesis of PHACE syndrome.
Journal of Investigative Dermatology (2013) 133, 677–684; doi:10.1038/jid.2012.367; published online 25 October 2012
INTRODUCTION
Children with large infantile hemangiomas on the face and
scalp are at risk for associated birth defects. Pascual-
Castroviejo (1978b) described a female patient with a facial
hemangioma and Dandy–Walker syndrome with abnormal
intracranial cerebral arteries. He subsequently described
seven additional female patients with hemangioma and
neurovascular anomalies (Pascual-Castroviejo, 1978a). In
1985, the term sternal malformation/vascular dysplasia
syndrome was used to describe a child with sternal cleft and
cutaneous craniofacial hemangiomas as well as airway and
liver hemangiomas (Hersh et al., 1985). Frieden et al. (1996)
proposed the acronym PHACE (Posterior fossa malformations,
infantile Hemangiomas, Arterial anomalies of the great
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cerebral vessels, Coarctation of the aorta, Eye anomalies, and
sternal defects) to describe this condition (OMIM: 606519).
Children with PHACE are at risk for cerebral vasculopathy,
which can lead to arterial ischemic stroke in a subset of
individuals (Drolet et al., 2006; Siegel et al., 2012).
Hemangiomas on the lower body can be associated with
congenital anomalies in LUMBAR syndrome (Lower body
hemangioma, Urogenital anomalies, ulceration, Myelopathy,
Bone deformities, Anorectal or arterial anomalies, and Renal
anomalies) (Iacobas et al., 2010). In recent times, there has
been a surge in the identification of the genes involved with
the overgrowth syndromes associated with vascular malfor-
mations (Kurek et al., 2012; Riviere et al., 2012); however, the
genes associated with the hemangioma syndromes have yet to
be elucidated.
All reported cases of PHACE to date have been sporadic;
yet, the consistent phenotype and the characteristic brain and
aortic anomalies provide evidence for a genetic etiology.
PHACE has a significant female predominance, suggesting
that there may be a contribution from the X chromosome or
hormonal influences (Haggstrom et al., 2007). X-linked
inheritance has been suggested, yet male patients do not
have increased severity (Levin and Kaler, 2007; Metry et al.,
2008). Preliminary X-inactivation studies in this PHACE cohort
did not identify significant skewing in most affected female
patients or in their mothers (Molecular Syndromology, 2013).
Although linkage studies have been conducted on solitary
infantile hemangiomas identifying a locus at 5q, and
subsequent studies have pointed to the involvement of
VEGFR2 (Walter et al., 1999; Jinnin et al., 2008), no linkage
studies have been conducted on PHACE specifically. There
have been no significant prenatal environmental factors or
toxins identified in association with PHACE (Metry et al.,
2006).
There is growing evidence that small structural chromoso-
mal abnormalities contribute to a broad array of complex
congenital malformations (Southard et al., 2012). High-density
arrays now provide a powerful method for evaluating genome-
wide copy number variation (CNV) and have been used to
advance knowledge of the genetic basis of numerous disorders
including thoracic aortic aneurysms (Prakash et al., 2010),
autism spectrum disorders (Glessner et al., 2009), and
developmental brain disorders (Aldinger et al., 2009; Pinto
et al., 2010). The objective of this study was to compre-
hensively evaluate the contribution of CNV in PHACE
syndrome.
RESULTS
Ninety-eight individuals diagnosed with PHACE were geno-
typed and analyzed for CNVs. Of them, 94 individuals with
PHACE were genotyped using the Affymetrix Human Mapping
GeneChip 6.0 array (Santa Clara, CA) and analyzed with the
Genotyping Console Software (Figure 1: flowchart of CNV
analysis and identification). A collaborating group also pro-
vided data on an additional cohort of four individuals with
PHACE, which were run and analyzed with the Roche
Nimblegen programs (Madison, WI), and these results were
included in this analysis (see Supplementary Methods online).
Eighty-two individuals with PHACE were female and 16 were
male. Additional demographic data have been summarized in
Table 1. A control group included 91 individuals without
PHACE from an unrelated research cohort (see Materials and
Methods for a description of this cohort).
CNV in 98 PHACE syndrome cases
First, we looked at CNV burden and found a total of 3,696
CNVs (2,473 duplications and 1,223 deletions) in 94 indivi-
duals with PHACE using the Genotyping Console, averaging
39 CNVs per individual (18–83 CNVs) with a mean length of
328kb (range: 25kb–23.8MB). In the control cohort of 91
individuals, a total of 3,484 CNVs (2,506 duplications and
978 deletions) were identified, averaging 38 CNVs per
individual (18–91 CNVs) with a mean length of 267 kb
(25 kb–23.4MB). The average number of CNVs per individual
was not found to be statistically different between subjects and
controls (P¼0.91). In data provided by the collaborating
group from the additional cohort of four individuals with
PHACE, a total of 76 CNVs (34 duplications and 42 deletions)
with a mean length of 373kb (range: 27 kb–3.9Mb) were
detected using the Roche NimbleGen array. Thus, a total of
3,772 CNVs (2,507 duplications and 1,265 deletions) were
detected in 98 individuals with PHACE syndrome. The CNVs
were then eliminated from further analysis if they failed to
meet established criteria for quality, spanned centromeres, or
did not contain genes. Of the CNVs meeting our criteria as
described in Figure 1, only two CNVs were excluded, on the
basis of identification in the control cohort (1q34 and 2p13.2).
In these 98 individuals with PHACE, we identified rare CNVs
greater than 100 kb at 1q32.1, 1q43, 3q26-3q26.33, 3p11.1,
7q33, 10q24.32, 12q24.13, 17q11.2, 18p11.31, and Xq28.
The genes contained in the reported CNVs are shown in
Supplementary Table 1 online, and clinical phenotypes are
detailed in Supplementary Table 2 online. There were no rare
CNV events that occurred in more than one individual with
PHACE.
Validation
Taqman quantitative PCR (qPCR) was used to validate nine
discovered rare CNV regions. The 7q33 region was validated
with the Nimblegen chip. Taqman probes for selected genes in
each genomic region were designed as follows: (1) KLHL12,
CYB5R1, and PPFIA4 (1q32.1), (2) FH and KMO (1q43), (3)
PIK3CA and MFN1 (3q26.32-3q26.33), (4) EPHA3 (3q11.1),
(5) ARL3 (10q24.32), (6) TPCN1 and SLC24A6 (12q24.13), (7)
TNFAIP1 and VTN (17q11.2), (8) EMILIN2 and MYOM1
(18p11.31), and (9) AFF2 (Xq28). Additional candidate regions
(tested but not listed above) that failed to validate with
Taqman qPCR were excluded from further analysis.
De novo versus inherited CNVs
The de novo versus inherited status was determined by testing
the mother and father for the identified CNV using the Taqman
qPCR analysis. Parental DNA for either one or both
parents was not available for five cases. Inherited CNVs
included 1q32.1, 3p11.1, 10q24.32, 17q11.2, and 18p11.31
(Supplementary Table 1 online). De novo status for all other
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validated CNVs was indeterminate, as one or both parental
DNA samples were unavailable for analysis.
Functional network pathway analysis
We screened the CNV regions for known genes important
in vasculogenesis, such as TGFBR1, TGFBR2, VEGF,
NOTCH1, and NOTCH2; however, CNVs containing
these specific genes were not identified in this cohort. As a
next step in the analysis, validated CNVs were analyzed
with the Ingenuity program to identify gene networks and
enrich for common pathways (see Materials and Methods).
The analysis identified direct and indirect interactions between
the genes in the CNV and the AKT/PIK3/VEGF (vascular
endothelial growth factor) pathways (Figure 2). A duplication
containing the gene PIKC3A is of interest because phos-
phoinositide 3-kinase catalytic subunit-a (C3A) has indirect
interactions with mammalian target of rapamycin, nitric
oxide synthase 2, EGF, and hypoxia-inducible factor 1a
(HIF-1a) and a direct interaction with ERK and AKT1. MYOG,
CYP17A1, and CHI3L1 also showed interactions with these
pathways.
DISCUSSION
As a first step in determining the genetic influence in the
development of PHACE, we utilized genome-wide CNV
analysis in a discovery cohort of 98 individuals with PHACE
to evaluate CNV regions. This is the largest series to date
analyzing the contribution of CNV in PHACE. We report here
several rare CNVs (see Materials and Methods for selection
criteria), which were not found in the database of genomic
variants (DGV). We have further reviewed the CNVs in the
database of genomic structural variation (dbVar, http://www.
ncbi.nlm.nih.gov/dbvar/studies/nstd54/) containing a data set
with copy number variants from 15,767 children with deve-
lopmental delay. There was no overlap between the CNVs in
individuals with PHACE and the CNVs reported as pathogenic
Controls
100 CAD samples
Genotyped on the Affymetrix Human Mapping GeneChip 6.0 arrays
Excluded low-quality
and duplicate samples
Cases
94 PHACE samples
Controls
91 CAD samples
Genotyped on the Roche Nimblegen human
CGH 3 × 720K whole-genome tiling array
Cases
4 PHACE samples
Selected CNVs with 10 data points or more
and had a log2 ratio greater than ± 0.3
Excluded any sample with a quality score
greater than 0.3
Excluded small events (size<100 kb)
Excluded common polymorphisms
(>5% overlap with CNVRs reported
in DGV or in controls)
Excluded CNVs containing
solely non-genic regions
Validated identified CNVs using Applied Biosystems
TaqMan qPCR or Roche Nimblegen array
Analyzed with Genotyping Console
Software-Affymetrix program
Cases
118 PHACE samples
Excluded small events (size<100 kb)
Determined de novo status of identified CNV
using Applied Biosystems TaqMan qPCR with
available parent DNA samples
Validated CNV were cross-referenced against the
CNVs in a cohort with developmental delay:
http://www.ncbi.nlm.nih.gov/dbvar/studies/
nstd54/
Analyzed with (1) Roche Nimblegen
Nimblescan and SignalMap, (2) BioDiscovery
Nexus copy number software
Excluded sample data exhibiting greater
than 1% variability in the genome
Figure 1. Flowchart of copy number variation (CNV) analysis and identification. Algorithm used to identify large and rare CNVs in 98 individuals with PHACE
syndrome. CAD, coronary artery disease cohort; CNVR, copy number variation region; DGV, database of genomic variants; qPCR, quantitative reverse
transcriptase in real time.
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in the publication from Cooper et al. (2011). Overlap was
noted with the CNVs recorded in dbVar from the Cooper
cohort; however, the majority of the reported overlapping
CNVs were much larger, encompassing several additional
genes. In the dbVar database, there was no reported clinical
interpretation, validation, or testing of inheritance for these
CNVs. As these variants have not been previously linked with a
specific disease phenotype other than developmental delay,
and in rare cases with craniofacial dysmorphism or unspecified
abnormalities of the cardiovascular system, they should be
considered ‘‘variants of unknown significance’’ until larger data
sets for PHACE are investigated or functional studies are
conducted. In this study, we did not find any large, rare
CNVs occurring in more than one individual with PHACE.
The CNVs reported in this paper contain genes that interact
with the HIF-1a, VEGF, AKT, and mammalian target of
rapamycin pathways (Figure 2), which have been implicated
in angiogenesis and hemangioma pathogenesis (Chen et al.,
2005; Boscolo et al., 2011; Karar and Maity, 2011). The CNV
gain at 3q26.32 contains the PIK3CA gene. PIK3CA interacts
with AKT1, VEGF, and HIF-1a (Figure 2). PIK3CA, specifically,
has been demonstrated to promote angiogenesis through
VEGF with a positive correlation between PIK3CA and VEGF
expression in ovarian cancer cells (Zhang et al., 2003).
Mutations in the PIK3CA gene have recently been impli-
cated in a condition characterized by megalencephaly and
growth dysregulation with variable asymmetry, skin capillary
malformations, distal limb malformations, and variable
cortical malformation (MCAP) (Mirzaa et al., 2012; Riviere
et al., 2012). In addition, PIK3CA gene mutations have been
identified in CLOVES syndrome (Congenital Lipomatous
Overgrowth with Vascular, Epidermal, and Skeletal anomalies)
(Kurek et al., 2012). The 1q32.1 region also contains the
liprin-a4 gene promoter (PPFIA4), which is directly activated
by binding of the HIF-1a (Mattauch et al., 2010). HIF-1a
functions as a transcriptional regulator of the adaptive
response to hypoxia and has a role in embryonic
vascularization. A portion of the MYOM1 gene was present
in both a 26-kb loss and a 247-kb gain in two unrelated
individuals with PHACE. The significance of this finding is
uncertain. The myomesin genes have an important structural
Table 1. Clinical characteristics of 98 individuals with
PHACE syndrome
Category
Number of individuals with
PHACE (total: 98)
Gender
Female 82
Male 16
Female:male ratio 5:1
Age at enrollment1
Mean 35.3 Months
Range 1 Month–30 years
Gestational age (weeks)2
Mean 38.7
Range 32–42
Ethnicity
Hispanic or Latino 23
Non-Hispanic or non-Latino 60
Other/unknown/NA 15
Race
American Indian/Alaska native 1
Asian 3
Native Hawaiian or other
Pacific Islander
0
Black or African American 2
White 86
Other/unknown/NA 6
Family history of infantile hemangioma
Yes 8
No 28
Unknown/NA 62
PHACE phenotype
Brain malformations 33/85 (39%)
Infantile hemangioma 90/90 (100%)
Arterial anomalies 69/80 (86%)
Aortic anomalies 30/87 (34%)
Congenital eye abnormalities 27/84 (32%)
Sternal malformations 22/86 (26%)
Maternal factors Number of mothers (total: 98)
Age at time of delivery (years)3
Mean 30
Range 20–44
Pre-eclampsia
Yes 10
No 60
Unknown/NA 28
Hypertension
Yes 14
No 58
Unknown/NA 26
Table 1 (Continued )
Category
Number of individuals with
PHACE (total: 98)
Number of previous miscarriages4
Mean 0.43
Range 0–5
Abbreviation: NA, information not available.
1Information for age at enrollment was available for 88 of 98 individuals
with PHACE syndrome.
2Information for gestational age was available for 80 of 98 individuals with
PHACE syndrome.
3Information for maternal age at delivery was available for 76 mothers.
4Information for number of previous miscarriages was available for 65
mothers.
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and functional role in striated muscle, and myomesin
mutations have been identified in a family with hypertrophic
cardiomyopathy (Siegert et al., 2011).
Genes involved with embryonic development
The candidate gene VTN in region 17q11.2 interacts with
a biological network involved in embryonic cranial
mesenchyme and vascular tissue development, as well as
with endothelial–mesenchymal interactions in development
(Arciniegas et al., 2006). Such interactions with the cranial
mesenchyme have been shown to be important in normal
cerebellar development, and disruption can lead to Dandy–
Walker malformation (Aldinger et al., 2009). This CNV in this
female proband was inherited from the mother; therefore, we
GRIA2
EXOC4
PPFIA4
PLCG1
GNAQ
MFN1
TSC22D1
POLDIP2
AFF2
UBF1
LPIN2
FOXO1
CTNNB1
BRG1A
GRIP1
MYC
KLHL12
TMEM97
MYOD1
MYBPHUBC
CYB5R1
CHIT1 EPO CAV3
MYOG
MTOR
RAC1 PIK3CA
CRK
P38 MAPK
SLC46A1
GNAI3
MEF2C
SRF GNAI1
C-FOS1
IGF2
SP1
TNF
ADORA1
KMO
MMP12
CHI3L1
P2RY2
MMP9NFKB1
EGFR
MYOM1
ITGB3
ITGA2B
RELA
ADIPOR1
CYP17A1 POMC
IGFBP5
MMP3
VEGF 121
PI3K
APPL1
VTN
EFNB2
MMP2
Rac
Vegf
SARM1
TGFB1
FGF2
IGF1
NOS2 SERPINE1
EGF
CBL
TICAM1 IRS1
EPHA3
PTEN
TNFAIP1
EMILIN2
ABL1
FH
APC
GRB2
FYN
RHOA
HIF-1 ALPHA 736
CDC42
AKT1
ADRBK1
Nitric oxide
ERK1/2
NSRC6
GNAI2
NCOA2
MET
HRAS
RHOG
Figure 2. Network of interacting PHACE syndrome copy number variation (CNV) genes. Genes within the PHACE-associated CNVs were analyzed using the
Ingenuity Software Program (http://ingenuity.com). Genes with CNV gains are shown in blue and CNV losses are shown in red. All CNVs in this network are rare,
not seen in the database of genomic variants or in 91 controls from the study. Arrows indicate the action of one molecule on another. Lines between two molecules
indicate binding only. Solid lines indicate direct interactions and dashed lines indicate indirect interactions.
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consider this to be a variant of unknown significance. A gain
of the ephrin receptor tyrosine kinase (EPHA3) gene at
chromosome 3p11.1 was identified in an individual with a
sternal cleft and supraumbilical raphe. EPHA3 is involved in
the guidance and coordination of the migration of motor and
sensory axons during development and in cardiac valve
development (Oates et al., 1999; Jayasena et al., 2005;
Stephen et al., 2007; Bevins et al., 2011). A gain of the
ADORA1 gene was found in a patient with arterial anomalies
and coarctation of the aorta. The adenosine A1 receptor
(ADORA1) gene has been shown to participate in axon
guidance for the retino-tectal patterning through engrailed
homeoprotein transcription factors and ephrin A5 (Stettler
et al., 2012). It is notable that a gain in the EMILIN2 gene
at 18p11.31 was identified in a patient with a posterior
fossa malformation and both carotid and cerebral arterial
anomalies. EMILIN2 protein expression has been demon-
strated in the mouse heart and aorta (Doliana et al., 2001;
Sa and Hoover-Plow, 2011). Fibrosis and decreased elastic
fibers seen in aorta tissue after coarctation repair have been
reported, suggesting that abnormalities in elastic fibers could
potentially have a role in the pathogenesis of PHACE (Prada
et al., 2010).
Summary
PHACE is a complex condition that is likely to have multi-
factorial risk factors. Although several rare CNVs were identi-
fied in this cohort, none were found in more than one patient.
Five discovered CNVs, 1q32.1, 3p11.1, 10q24.32, 17q11.2,
and 18p11.31, were inherited, although there was no family
history of either PHACE or infantile hemangiomas in any of
these individuals. It is interesting to note that the chromosomal
regions 1q32.1, 3p11.1, 10q24.32, 17q11.2, and 18p11.31
were enriched for genes involved in the HIF-1a, VEGF, and
mammalian target of rapamycin signaling pathways. Larger
data sets will be necessary to determine the significance of the
CNVs reported in this manuscript. These findings are consis-
tent with our current understanding of PHACE as a complex
condition, and more sophisticated approaches, including next-
generation sequencing of both germline and tissue DNA, will
likely be necessary to determine whether genetic factors are
involved in the pathogenesis of this disorder.
Limitations
The greatest challenges of CNV analysis are discrimination
of the effects of common and rare CNV polymorphisms and
the disease relevance of structural chromosomal abnormal-
ities. We used the existing databases of published CNVs
including the University of California Santa Cruz Genome
Browser, the DGV, and others to filter variants that appear to
be common in the general population. We recognize that a
limitation of this study is that we may have excluded some of
the CNVs with a potential influence in PHACE based on a
previously reported association with a different disorder.
When available, we used a family-based approach to deter-
mine the de novo status. Array CNV analysis is limited by its
resolution to detect events. It is also possible that the coronary
artery disease control group may have shared some common
CNVs with the PHACE cohort, wherein the causative CNV
could have been masked. We recognize this as another
limitation of this study.
MATERIALS AND METHODS
For additional methods for the samples run on Nimblegen array, see
Supplementary Methods online.
Study populations
The study has ongoing approval from the Institutional Review
Board (IRB) at Children’s Hospital of Wisconsin and was approved
previously by the IRBs at Oregon Health and Science University, the
University of Utah, and the Committee for Human Research at the
University of California at San Francisco. Written informed consent
was obtained from all study subjects upon enrollment into the PHACE
International Clinical Registry and Genetic Repository and includes
information about DNA sharing and on the Database of Genotypes and
Phenotypes as well as on adherence to the Declaration of Helsinki
Principles. Ninety-four individuals with PHACE were genotyped on the
Affymetrix Human Mapping GeneChip 6.0 array and analyzed with
the Genotyping Console Software-Affymetrix program. The diagnosis of
a definite or possible syndrome was made at participating institutions
using previously described criteria (Metry et al., 2009) and confirmed
by a central review of magnetic resonance imaging, magnetic
resonance angiography, or echocardiogram reports. Internal controls
for the study included 91 subjects with coronary artery disease who did
not carry a diagnosis of PHACE. Individuals in the control cohort were
adults with coronary artery disease consented under an unrelated
research protocol, which allows DNA information sharing for research-
related purposes. Parent and control cohorts were genotyped on the
same platform and subjected to equivalent quality control measures
and CNV analysis used for affected cases.
DNA and tissue repository
The DNA and tissue repository for the PHACE syndrome International
Clinical Registry and Genetic Repository has been maintained in the
Children’s Research Institute at MCW. DNA was extracted from saliva
obtained from buccal swabs and from blood collected from
each subject (4ml in an EDTA tube). The quantity and quality of
the DNA were measured using the Nanodrop (Thermo Scientific,
Wilmington, DE).
Genotyping and CNV data analysis and novelty assessment
Two hundred eighteen samples (118 PHACE subjects and 100 control
samples) were hybridized to the Affymetrix 6.0 GeneChips. Genotyp-
ing was performed with the Affymetrix Human Mapping GeneChip
6.0 arrays to assay a minimum of roughly 1.9M probes for analysis as
per standard protocol (see Supplementary Methods online). CEL files
were exported to the Genotyping Console (Affymetrix) for analysis as
per standard protocols. Stringent quality parameters were applied.
Samples with greater than 92 CNV segments as well as out-of-bound
and duplicate patient samples were excluded from further analysis,
resulting in a total of 94 patients with PHACE and 91 controls for the
study. Regions of CNV in our participants with PHACE were
compared with CNVs previously reported in public CN databases
(Toronto DGV, http://projects.tcag.ca/cgi-bin/variation/gbrowse/hg19/)
to determine regions that were novel to individuals with PHACE.
DH Siegel et al.
Copy Number Variation in PHACE Syndrome
682 Journal of Investigative Dermatology (2013), Volume 133
An additional search for CNV regions in decipher (http://decipher.
sanger.ac.uk/) was conducted to look for any associated phenotypes
and in OMIM (http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim)
for known diseases. Candidate genes within discovered genomic
regions were determined for their potential role in disease pathogen-
esis based on information gathered from sources in PubMed (http://
www.ncbi.nlm.nih.gov/pubmed/), University of California Santa Cruz
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway), and
Ingenuity (http://ingenuity.com/). We used the following criteria for
CNV detection: (1) size greater than 100 kb,( 2) less than 5% overlap
with reported CNVs in the DGV or in our control cohort; and (3)
inclusion only of regions containing genes. CNVs with a less than
100-kb copy loss or gain were noted if found within a larger CNV
region discovered in another individual. An average distance between
markers ofp2kb was required to determine adequate probe density.
Once rare CNVs were discovered in our patient cohort, validation
was performed with the Applied Biosystems TaqMan qPCR (Carlsbad,
CA), and de novo status was ascertained when parental genotypes
were available. Finally, the validated CNVs were cross-referenced
against the published neurodevelopmental CNVs at http://
www.ncbi.nlm.nih.gov/dbvar/studies/nstd54/ (Cooper et al., 2011).
qPCR validation
Findings from our CNV analysis with the genotyping console were
validated with the Applied Biosystems TaqMan qPCR. Primers and
probes used to detect CNVs with qPCR were ordered from Applied
Biosystems (pre-mixed assay) (see Supplementary Methods online).
Functional analysis: Ingenuity network pathways
Candidate genes within discovered genomic regions from CNV
analysis with the Genotyping Console were imported into the
Ingenuity Pathways Analysis (IPA) Web server for functional analysis
(maximum 35 genes). The IPA software utilizes the Ingenuity Knowl-
edge Base (http://ingenuity.com, accessed January 2012), which
contains information on millions of biological interactions and
functional annotations derived from published data. This referenced
information is used to model relationships between genes, proteins,
complexes, cells, cellular components, and diseases among other
molecules. The Path Explorer function of the IPA program searches for
interactions between genes and was used to create the shortest
interconnected pathway for genes contained in detected CNV
regions. Shared pathways were subsequently noted.
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